New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
10:17 EDTCTRX, ESRXAnalyst says Express Scripts won't be hurt by private exchanges
Express Scripts (ESRX), which provides pharmacy benefit management services, is unlikely to be significantly hurt by private health insurance exchanges, research firm Jefferies believes. Investor worries about the impact of such exchanges on the company is overdone, the firm added. WHAT'S NEW: Following reports yesterday that several major companies are looking to place their retired workers into a private health insurance exchange, Jefferies analyst Brian Tanquilut wrote that such exchanges have been around for several years and have not significantly affected Express Scripts or its competitors. Moreover, many investors do not realize that Express Scripts' profit margins from the exchanges are not much lower than its margins from the large companies, Tanquilut contended. Finally, as a result of the shift of beneficiaries onto private exchanges, Express Scripts will have the opportunity to win new customers currently covered by its competitors, the analyst believes. He expects the stock to start advancing in the fourth quarter of this year and kept a Buy rating on the shares. WHAT'S NOTABLE: Express Scripts' stock fell slightly in an up market yesterday, as did shares of its competitor Catamaran (CTRX). TODAY'S PRICE ACTION: In early trading today, Express Scripts added 0.5% to $65 and Catamaran rose 0.45% to $45.60
News For ESRX;CTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
10:08 EDTESRXExpress Scripts calls active
Subscribe for More Information
January 29, 2016
10:13 EDTESRXExpress Scripts to exclude Valeant's Glumetza from formulary
Subscribe for More Information
January 28, 2016
06:24 EDTESRXAnthem added to Focus List at Citi
Citi analyst Ralph Giacobbe added Anthem (ANTM) to his firm's Focus List. As Anthem and Express Scripts (ESRX) continue to negotiate their pharmacy benefits manager contract, the analyst sees UnitedHealth (UNH) as a potential alternative for Anthem. Regardless of the outcome, Anthem is in the "driver's seat for significant savings/upside," which is not reflected in the stock. Giacobbe tells investors in a research note. He keeps a Buy rating on the name with a $172 price target.
January 25, 2016
15:24 EDTESRXExpress Scripts off highs after Clinton tweets critical NPR report
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use